Lung cancer: treatment
First-line treatment for non-small cell lung cancer is surgery; but many patients are not suitable and, for these patients, management may involve radiotherapy, chemotherapy or newer targeted therapies
Surgery provides the best chance of cure for patients with stage I and II non-small cell lung cancer (NSCLC). However, many patients with early NSCLC are not suitable for surgery and, for such patients, radiotherapy is the treatment of choice.
First-line treatment of patients with advanced NSCLC is usually with a chemotherapy regimen that includes one platinum-based drug plus a third-generation medicine (eg, paclitaxel). In recent years the use of targeted treatments (eg, erlotinib or gefitinib) has improved outcomes for patients with advanced NSCLC.
The full text article is available as a PDF (940K) file.
Steve Williamson is a consultant pharmacist for cancer services at Northumbria Healthcare NHS Trust and North of England Cancer Network
Simon Purcell is a specialist oncology pharmacist and teacher practitioner at Clatterbridge Centre for Oncology NHS Foundation Trust
This is one of two Clinical focus articles in the April 2011 issue of Clinical Pharmacist (diagnosis and staging of disease and treatment) that are linked to a Centre for Pharmacy Postgraduate Education learning@lunch flex module on lung cancer — designed for hospital pharmacists and technicians in England.
You can use these articles to provide key background knowledge on the topic before participating in a learning@lunch flex session at your hospital. The module contains reflective questions, case studies and practice activities to allow you to put your learning into action.
You can order copies of this module via your CPPE key contact at the hospital or by emailing Jayne Plant on firstname.lastname@example.org
Now put your learning into practice by joining colleagues at a CPPE learning@lunch flex session in your hospital.
During the session you will test your knowledge with five reflective questions and three true-to-life case studies.
You will discuss the most appropriate treatment strategy for lung cancer while focusing on the emergency admission of Mrs Brown.
Our other case studies will explore the place of erlotinib in therapy and the management of chemotherapy-induced nausea and vomiting.
For more information about taking part in a learning@lunch flex session or setting up your own learning community, turn to the contact details above.
Citation: Clinical Pharmacist URI: 11072147
Recommended from Pharmaceutical Press